Exelixis

This early-phase study tests a new drug, XB371, in about 150 adults with advanced solid tumors that have come back or spread. The main goal is to check the drug's safety and find the right dose. Participants must be in fairly good health and have a life expectancy of at least 12 …

This study compares a new drug, zanzalintinib, to the current standard everolimus in people with advanced neuroendocrine tumors that have already been treated. The goal is to see which drug better slows cancer growth. About 440 adults with pancreatic or other neuroendocrine tumor…

This early-phase study tests a new drug called XB628 in about 75 people with advanced solid tumors that have not responded to standard treatments. XB628 is designed to help the body's natural killer cells attack cancer cells more effectively. The main goals are to find a safe dos…

This early-phase study tests a new drug called XB010, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for any side effects. About 396 adults with…

This early-stage study tests a new drug called XL309, alone or with another drug (olaparib), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About …

This early-stage trial tests a new drug called XL092, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their gro…